Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Frequently asked questions
What sector does Sandoz Group AG (SDZ) operate in?
Sandoz Group AG belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Sandoz Group AG (SDZ) current stock price?
As of the latest data, Sandoz Group AG stock price is CHF 73.72, with a previous close of CHF 72.64. Sandoz Group AG gained CHF 1.08 in the last trading session, representing a 1.49% increase.
What is Sandoz Group AG (SDZ) current market capitalization?
Sandoz Group AG market cap is approximately 31.90 billion.
What is Sandoz Group AG (SDZ) Earnings Per Share (EPS)?
The trailing EPS is CHF 1.78, and the forward EPS is CHF 4.56.
What is Sandoz Group AG (SDZ) Price-to-Earnings (P/E) ratio?
Sandoz Group AG current P/E ratio is 41.42, with a forward P/E of 16.16.
Does Sandoz Group AG (SDZ) pay dividends?
Yes. Sandoz Group AG pays annual dividends with an annualized yield of 1.09% and an estimated annual payout of CHF 0.80 per share.
When is the next ex-dividend date for Sandoz Group AG (SDZ)?
The next ex-dividend date is scheduled for April 13, 2027.
When is Sandoz Group AG (SDZ) next earnings report?
Sandoz Group AG is expected to release its next earnings report on June 30, 2026.
What is Sandoz Group AG (SDZ) beta (volatility) score?
Sandoz Group AG has a beta of 0.492, indicating lower volatility than the overall market.
